The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
The better understanding of the immunopathogenesis of psoriasis has led to the development of highly efficacious targeted therapies with favorable safety profiles. Among them, the class of Interleukin (IL)-17 antibodies are well established for the treatment of psoriasis, psoriatic arthritis and axi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/1/35 |
| _version_ | 1797625521492721664 |
|---|---|
| author | Georgios Kokolakis Kamran Ghoreschi |
| author_facet | Georgios Kokolakis Kamran Ghoreschi |
| author_sort | Georgios Kokolakis |
| collection | DOAJ |
| description | The better understanding of the immunopathogenesis of psoriasis has led to the development of highly efficacious targeted therapies with favorable safety profiles. Among them, the class of Interleukin (IL)-17 antibodies are well established for the treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Bimekizumab is a new antibody that simultaneously neutralizes IL-17A and IL-17F. We present two patients with psoriasis, who lost response to several biologics, among them IL-17 antagonists such as secukinumab, ixekizumab or brodalumab. Besides plaque-type psoriasis, patients also had psoriasis in hard-to-treat areas such as scalp and groins or psoriatic arthritis. Remarkably, both patients already responded to the therapy with bimekizumab 4 weeks after the first injection and, one year thereafter, both patients sustained PASI100. No side effects were observed. The fast response to bimekizumab emphasizes the crucial role of IL-17F in the pathogenesis of psoriasis. Besides, due to the new mechanism of action, non-responders to other anti-IL-17 therapies could benefit when switched to bimekizumab. |
| first_indexed | 2024-03-11T09:57:37Z |
| format | Article |
| id | doaj.art-1b78c04c43664acdb63ce9dcfe960206 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T09:57:37Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-1b78c04c43664acdb63ce9dcfe9602062023-11-16T15:40:29ZengMDPI AGJournal of Clinical Medicine2077-03832022-12-011213510.3390/jcm12010035The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A TherapyGeorgios Kokolakis0Kamran Ghoreschi1Psoriasis Research and Treatment Centre, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, GermanyDepartment of Dermatology, Venereology and Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, GermanyThe better understanding of the immunopathogenesis of psoriasis has led to the development of highly efficacious targeted therapies with favorable safety profiles. Among them, the class of Interleukin (IL)-17 antibodies are well established for the treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Bimekizumab is a new antibody that simultaneously neutralizes IL-17A and IL-17F. We present two patients with psoriasis, who lost response to several biologics, among them IL-17 antagonists such as secukinumab, ixekizumab or brodalumab. Besides plaque-type psoriasis, patients also had psoriasis in hard-to-treat areas such as scalp and groins or psoriatic arthritis. Remarkably, both patients already responded to the therapy with bimekizumab 4 weeks after the first injection and, one year thereafter, both patients sustained PASI100. No side effects were observed. The fast response to bimekizumab emphasizes the crucial role of IL-17F in the pathogenesis of psoriasis. Besides, due to the new mechanism of action, non-responders to other anti-IL-17 therapies could benefit when switched to bimekizumab.https://www.mdpi.com/2077-0383/12/1/35psoriasisscalp psoriasispsoriasis arthritisbimekizumabIL-17IL-23 |
| spellingShingle | Georgios Kokolakis Kamran Ghoreschi The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy Journal of Clinical Medicine psoriasis scalp psoriasis psoriasis arthritis bimekizumab IL-17 IL-23 |
| title | The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy |
| title_full | The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy |
| title_fullStr | The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy |
| title_full_unstemmed | The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy |
| title_short | The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy |
| title_sort | clinical significance of simultaneous il 17a and il 17f blockade in psoriasis non responding to anti il17a therapy |
| topic | psoriasis scalp psoriasis psoriasis arthritis bimekizumab IL-17 IL-23 |
| url | https://www.mdpi.com/2077-0383/12/1/35 |
| work_keys_str_mv | AT georgioskokolakis theclinicalsignificanceofsimultaneousil17aandil17fblockadeinpsoriasisnonrespondingtoantiil17atherapy AT kamranghoreschi theclinicalsignificanceofsimultaneousil17aandil17fblockadeinpsoriasisnonrespondingtoantiil17atherapy AT georgioskokolakis clinicalsignificanceofsimultaneousil17aandil17fblockadeinpsoriasisnonrespondingtoantiil17atherapy AT kamranghoreschi clinicalsignificanceofsimultaneousil17aandil17fblockadeinpsoriasisnonrespondingtoantiil17atherapy |